Dr. William Williams reports

BRIACELL'S BRIA-IMT DEMONSTRATES SURVIVAL ADVANTAGE OVER TRODELVY AND CONTROL GROUP IN METASTATIC BREAST CANCER

Briacell Therapeutics Corp. has released updated phase 2 survival data for its lead immunotherapy candidate, Bria-IMT, in combination with an immune checkpoint inhibitor (CPI).

The data show a meaningful survival advantage in heavily pretreated metastatic breast cancer (MBC) patient subtypes:

• Triple negative breast cancer (TNBC): median overall survival (OS) of 13.9 months versus 11.8 months for antibody-drug conjugate Trodelvy (sacituzumab govitecan-hziy) and 6.9 months single-agent chemotherapy data; Briacell's median OS has improved from 11.4 months last reported at ASCO (American Society of Clinical Oncology) in June, 2025;
• Hormone receptor positive (HR+): median overall survival (OS) of 17.3 months versus 14.4 months for Trodelvy and 11.2 months in single-agent chemotherapy data.

"We are thrilled to see our Bria-IMT regimen outperform established benchmarks like Trodelvy in TNBC and HR+ MBC patients," stated Dr. William V. Williams, Briacell's president and chief executive officer. "Briacell's patients had failed a median of six prior therapies, underscoring the potential clinical impact of our novel immunotherapy. We look forward to validating these findings in our ongoing pivotal phase 3 study with overall survival as its primary end point."

The phase 2 Bria-IMT study enrolled 54 heavily pretreated metastatic breast cancer patients (median number of prior treatments equal to six) who received the Bria-IMT regimen plus checkpoint inhibitor. Of these 54 patients, 37 received the same formulation currently being used in Briacell's continuing pivotal phase 3 study in metastatic breast cancer (listed on ClinicalTrials.gov as NCT06072612). No Bria-IMT-related discontinuations have been reported to date.

About Briacell Therapeutics Corp.

Briacell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care.

We seek Safe Harbor.